Literature DB >> 22711606

Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging.

Ramon F Barajas1, Joanna J Phillips, Rupa Parvataneni, Annette Molinaro, Emma Essock-Burns, Gabriela Bourne, Andrew T Parsa, Manish K Aghi, Michael W McDermott, Mitchel S Berger, Soonmee Cha, Susan M Chang, Sarah J Nelson.   

Abstract

Histopathologic evaluation of glioblastoma multiforme (GBM) at initial diagnosis is typically performed on tissue obtained from regions of contrast enhancement (CE) as depicted on gadolinium-enhanced, T1-weighted images. The non-enhancing (NE) portion of the lesion, which contains both reactive edema and infiltrative tumor, is only partially removed due to concerns about damaging functioning brain. The purpose of this study was to evaluate histopathologic and physiologic MRI features of image-guided tissue specimens from CE and NE regions to investigate correlations between imaging and histopathologic parameters. One hundred nineteen tissue specimens (93 CE and 26 NE regions) were acquired from 51 patients with newly diagnosed GBM by utilizing stereotactic image-guided sampling. Variables of anatomic, diffusion-weighted imaging (DWI), and dynamic susceptibility-weighted, contrast-enhanced perfusion imaging (DSC) from each tissue sample location were obtained and compared with histopathologic features such as tumor score, cell density, proliferation, architectural disruption, hypoxia, and microvascular hyperplasia. Tissue samples from CE regions had increased tumor score, cellular density, proliferation, and architectural disruption compared with NE regions. DSC variables such as relative cerebral blood volume, peak height, and recovery factor were significantly higher, and the percentage of signal intensity recovery was significantly lower in the CE compared with the NE regions. DWI variables were correlated with histopathologic features of GBM within NE regions. Image-guided tissue acquisition and assessment of residual tumor from treatment-naive GBM should be guided by DSC in CE regions and by DWI in NE regions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22711606      PMCID: PMC3379808          DOI: 10.1093/neuonc/nos128

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  58 in total

1.  Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology.

Authors:  Soonmee Cha; Glyn Johnson; Youssef Zaim Wadghiri; Olivier Jin; Jim Babb; David Zagzag; Daniel H Turnbull
Journal:  Magn Reson Med       Date:  2003-05       Impact factor: 4.668

2.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

3.  In vivo correlation of tumor blood volume and permeability with histologic and molecular angiogenic markers in gliomas.

Authors:  R Jain; J Gutierrez; J Narang; L Scarpace; L R Schultz; N Lemke; S C Patel; T Mikkelsen; J P Rock
Journal:  AJNR Am J Neuroradiol       Date:  2010-11-11       Impact factor: 3.825

4.  Abnormalities in the recirculation phase of contrast agent bolus passage in cerebral gliomas: comparison with relative blood volume and tumor grade.

Authors:  Alan Jackson; Andrea Kassner; Deborah Annesley-Williams; Helen Reid; Xiau-Ping Zhu; Kah-Loh Li
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825

5.  Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions.

Authors:  S Cha; S Pierce; E A Knopp; G Johnson; C Yang; A Ton; A W Litt; D Zagzag
Journal:  AJNR Am J Neuroradiol       Date:  2001 Jun-Jul       Impact factor: 3.825

6.  Choline metabolism, proliferation, and angiogenesis in nonenhancing grades 2 and 3 astrocytoma.

Authors:  Tracy R McKnight; Kenneth J Smith; Philip W Chu; King S Chiu; Colleen P Cloyd; Susan M Chang; Joanna J Phillips; Mitchel S Berger
Journal:  J Magn Reson Imaging       Date:  2011-04       Impact factor: 4.813

7.  MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas.

Authors:  Inas S Khayal; Scott R Vandenberg; Kenneth J Smith; Colleen P Cloyd; Susan M Chang; Soonmee Cha; Sarah J Nelson; Tracy R McKnight
Journal:  Neuro Oncol       Date:  2011-08-24       Impact factor: 12.300

8.  Correlation of immunohistologic and perfusion vascular parameters with MR contrast enhancement using image-guided biopsy specimens in gliomas.

Authors:  Rajan Jain; Jayant Narang; Jorge Gutierrez; Lonni R Schultz; Lisa Scarpace; Mark Rosenblum; Tom Mikkelsen; Jack P Rock
Journal:  Acad Radiol       Date:  2011-08       Impact factor: 3.173

9.  Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging.

Authors:  Ramon F Barajas; J Graeme Hodgson; Jamie S Chang; Scott R Vandenberg; Ru-Fang Yeh; Andrew T Parsa; Michael W McDermott; Mitchel S Berger; William P Dillon; Soonmee Cha
Journal:  Radiology       Date:  2010-02       Impact factor: 11.105

10.  Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics.

Authors:  Alexander C Guo; Thomas J Cummings; Rajesh C Dash; James M Provenzale
Journal:  Radiology       Date:  2002-07       Impact factor: 11.105

View more
  100 in total

1.  Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging.

Authors:  Rihyeon Kim; Seung Hong Choi; Tae Jin Yun; Soon-Tae Lee; Chul-Kee Park; Tae Min Kim; Ji-Hoon Kim; Sun-Won Park; Chul-Ho Sohn; Sung-Hye Park; Il Han Kim
Journal:  Eur Radiol       Date:  2016-06-29       Impact factor: 5.315

2.  ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain.

Authors:  K Welker; J Boxerman; A Kalnin; T Kaufmann; M Shiroishi; M Wintermark
Journal:  AJNR Am J Neuroradiol       Date:  2015-04-23       Impact factor: 3.825

3.  Pattern analysis of dynamic susceptibility contrast-enhanced MR imaging demonstrates peritumoral tissue heterogeneity.

Authors:  Hamed Akbari; Luke Macyszyn; Xiao Da; Ronald L Wolf; Michel Bilello; Ragini Verma; Donald M O'Rourke; Christos Davatzikos
Journal:  Radiology       Date:  2014-06-19       Impact factor: 11.105

4.  Performance of Standardized Relative CBV for Quantifying Regional Histologic Tumor Burden in Recurrent High-Grade Glioma: Comparison against Normalized Relative CBV Using Image-Localized Stereotactic Biopsies.

Authors:  J M Hoxworth; J M Eschbacher; A C Gonzales; K W Singleton; G D Leon; K A Smith; A M Stokes; Y Zhou; G L Mazza; A B Porter; M M Mrugala; R S Zimmerman; B R Bendok; D P Patra; C Krishna; J L Boxerman; L C Baxter; K R Swanson; C C Quarles; K M Schmainda; L S Hu
Journal:  AJNR Am J Neuroradiol       Date:  2020-03-12       Impact factor: 3.825

Review 5.  Radiogenomics and imaging phenotypes in glioblastoma: novel observations and correlation with molecular characteristics.

Authors:  Benjamin M Ellingson
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

6.  In vivo and ex vivo assessment of the blood brain barrier integrity in different glioblastoma animal models.

Authors:  Cindy Leten; Tom Struys; Tom Dresselaers; Uwe Himmelreich
Journal:  J Neurooncol       Date:  2014-07-03       Impact factor: 4.130

7.  Prognostic paradox: brain damage around the glioblastoma resection cavity.

Authors:  Takuya Furuta; Mitsutoshi Nakada; Fumiaki Ueda; Takuya Watanabe; Yasuaki Arakawa; Ryo Higashi; Masaaki Hashimoto; Hisashi Nitta; Yutaka Hayashi; Jun-ichiro Hamada
Journal:  J Neurooncol       Date:  2014-03-07       Impact factor: 4.130

8.  Emerging techniques and technologies in brain tumor imaging.

Authors:  Benjamin M Ellingson; Martin Bendszus; A Gregory Sorensen; Whitney B Pope
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

9.  Radiologically defined ecological dynamics and clinical outcomes in glioblastoma multiforme: preliminary results.

Authors:  Mu Zhou; Lawrence Hall; Dmitry Goldgof; Robin Russo; Yoganand Balagurunathan; Robert Gillies; Robert Gatenby
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

10.  Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics.

Authors:  Melissa A Prah; Mona M Al-Gizawiy; Wade M Mueller; Elizabeth J Cochran; Raymond G Hoffmann; Jennifer M Connelly; Kathleen M Schmainda
Journal:  J Neurooncol       Date:  2017-09-12       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.